The metabolism of the dual orexin receptor antagonist daridorexant

References

• Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. 2020. The Quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders. ChemMedChem. 15(23):2286–2305.
   PubMed Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, et al. 2007. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 13(2):150–155.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol. 22(23):3099–3108.
   PubMed Web of Science ®Google Scholar
• Citrome L. 2014. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 68(12):1429–1441.
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, McGaughey GB, Bednar RA, Lemaire W, Doran SM, et al. 2012. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem. 7(3):415–424, 337.
   PubMed Web of Science ®Google Scholar
• Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, et al. 2010. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 53(14):5320–5332.
   PubMed Web of Science ®Google Scholar
• de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, et al. 1998. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 95(1):322–327.
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Cruz HG, Gehin M, Hoever P. 2014. Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem. J Pharm Sci. 103(5):1548–1556.
   PubMed Web of Science ®Google Scholar
• Dopheide JA. 2020. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 26(4 Suppl):S76–S84.
   PubMed Web of Science ®Google Scholar
• Drahl C. 2014. As FDA decision loomed for suvorexant, chemist discussed sleep drug field’s big questions. Chem Eng News. 92(35):52–55.
   Google Scholar
• Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, et al. 2016. Suvorexant in patients with insomnia: results from two 3-months randomized controlled clinical trials. Biol Psychiatry. 79(2):136–148.
   PubMed Web of Science ®Google Scholar
• Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, Dayal S, Filippov G, Lalovic B, Moline M, et al. 2021. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmacol Drug Dev. 10(6):681–690.
   PubMed Web of Science ®Google Scholar
• Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, et al. 2015. Novel octahydropyrrolo[3,4-c]pyrroles as selective orexin-2 antagonists: SAR leading to a clinical candidate. J Med Chem. 58(14):5620–5636.
   PubMed Web of Science ®Google Scholar
• Matsuki T, Sakurai T. 2008. Orexins and orexin receptors: from molecules to integrative physiology. Results Probl Cell Differ. 46:27–55.
   PubMedGoogle Scholar
• Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T, 2022. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicenter, randomized, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 21(2):125–139.
   PubMedGoogle Scholar
• Miller TR, Witte DG, Ireland LM, Kang CH, Roch JM, Masters JN, Esbenshade TA, Hancock AA. 1999. Analysis of apparent noncompetitive responses to competitive H(1)-histamine receptor antagonists in fluorescent imaging plate reader-based calcium assays. J Biomol Screen. 4(5):249–258.
   PubMedGoogle Scholar
• Morin CM, Drake CL, Harvey AG, Krystal AD, Manber R, Riemann D, Spiegelhalder K. 2015. Insomnia disorder. Nat Rev Dis Primers. 1:15026.
   PubMed Web of Science ®Google Scholar
• Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, Croft M, van Gerven J, Krähenbühl S, Dingemanse J. 2019. Metabolism of the dual orexin receptor antagonist ACT-541468, based on microtracer/accelerator mass spectrometry. Curr Drug Metab. 20(4):254–265.
   PubMed Web of Science ®Google Scholar
• Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J. 2018. Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. 104(5):1022–1029.
   PubMed Web of Science ®Google Scholar
• Nevárez N, de Lecea L. 2018. Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation. F1000 Res. 7:F1000 Faculty Rev-1421.
   PubMedGoogle Scholar
• Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al. 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 92(4):573–585.
   PubMed Web of Science ®Google Scholar
• Seglen PO, Fossa J. 1978. Attachment of rat hepatocytes in vitro to substrata of serum protein, collagen, or concanavalin A. Exp Cell Res. 116(1):199–206.
   PubMed Web of Science ®Google Scholar
• Treiber A, Aissaoui H, Delahaye S, Glutz S, Grimont J, Müller C, Seeland S, Siefken V, Boss C. 2023. CYP3A4 catalyzes the rearrangement of the dual orexin receptor antagonist daridorexant to 4-hydroxypiperidinol metabolites. Chem Med Chem. e202300030. Online ahead of print.
   Google Scholar
• Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F. 2017. The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468. J Pharmacol Exp Ther. 362(3):489–503.
   PubMed Web of Science ®Google Scholar
• Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. 2019. Effect of CYP3A inhibition and induction on the pharmacokinetics of suvorexant: two phase I, open-label, fixed-sequence trials in healthy subjects. Clin Drug Investig. 39(5):441–451.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, et al. 2015. Discovery of (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist. J Med Chem. 58(11):4648–4664.
   PubMed Web of Science ®Google Scholar
• Zammit GK. 2007. The prevalence, morbidities, and treatments of insomnia. CNS Neurol Disord Drug Targets. 6(1):3–16.
   PubMedGoogle Scholar